Investors considering a purchase of Harrow Inc (Symbol: HROW) stock, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the ...
Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results